RAPA-501 Therapy for ALS — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RAPA-501 Therapy for ALS — Stella

Recruiting

Back to Amyotrophic Lateral Sclerosis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Massachusetts General Hospital, Boston, Massachusetts

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Rapa Therapeutics LLC

Collaborators

Massachusetts General Hospital

Enrollment target

~41 participants

Started

January 2025

Primary completion

July 2026

Age range

18 Years and older

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov